arginyl-glycyl-aspartic acid has been researched along with Triple Negative Breast Neoplasms in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dai, Z; Gong, Z; Jiang, X; Li, R; Liu, Y; Sun, D; Zeng, W; Zheng, G; Zhou, Y | 1 |
| Fu, Q; Guo, L; Peng, Y; Pu, Y; Wu, Y; Yue, Q; Zhang, H; Zhao, Y | 1 |
| Han, T; Huang, S; Ji, X; Kang, N; Liu, Y | 1 |
| Cheng, R; Deng, C; Gu, X; Meng, F; Zhong, P; Zhong, Z | 1 |
| Bae, Y; Huang, X; Jiang, Y; Lee, EY; Li, Y; Lin, HP; Reichel, D; Wang, Z; Xiao, Y; Yang, C | 1 |
| Blancafort, P; Clemons, TD; Dessauvagie, B; Evans, CW; Golden, E; Plani-Lam, JH; Redfern, AD; Sorolla, A; Swaminathan-Iyer, K; Wang, E | 1 |
| Cai, P; He, C; Henderson, JT; Lip, H; Rauth, AM; Wang, Z; Wu, XY; Zhang, T | 1 |
| Abuelela, AF; Bharath, AA; Chen, S; Douglas, T; Greenwood, C; Merzaban, JS; Othman, BA; Porter, AE; Ryan, M; Theodorou, I; Uchida, M | 1 |
| Bhanumathi, R; Bhattacharyya, A; Gunasekaran, P; Kannan, S; Murugan, C; Rayappan, K; Shanthi, K; Sivasubramanian, S; Thangam, R; Thirumurugan, R; Vivek, R | 1 |
| Cai, P; He, C; Prasad, P; Rauth, AM; Shan, D; Wu, XY; Zhang, T | 1 |
10 other study(ies) available for arginyl-glycyl-aspartic acid and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Asymmetric, amphiphilic RGD conjugated phthalocyanine for targeted photodynamic therapy of triple negative breast cancer.
Topics: Animals; Cell Line, Tumor; Humans; Isoindoles; Mice; Oligopeptides; Photochemotherapy; Triple Negative Breast Neoplasms | 2022 |
Dual-targeting liposomes with active recognition of GLUT
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Female; Fructose; Glucose Transporter Type 5; Humans; Integrin alphaVbeta3; Liposomes; Mice, Inbred BALB C; Molecular Targeted Therapy; Oligopeptides; Paclitaxel; Triple Negative Breast Neoplasms | 2019 |
Preparation of RGD4C fused anti-TNFα nanobody and inhibitory activity on triple-negative breast cancer in vivo.
Topics: Animals; Antineoplastic Agents, Immunological; Cell Line; Cell Line, Tumor; Cell Proliferation; Female; Fibroblasts; Gene Expression; Humans; Integrin alphaVbeta3; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Oligopeptides; Pichia; Recombinant Fusion Proteins; Single-Domain Antibodies; Triple Negative Breast Neoplasms; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2020 |
α
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Doxorubicin; Female; Humans; Integrin alphaVbeta3; Maytansine; Mice, Nude; Micelles; Molecular Targeted Therapy; Oligopeptides; Prodrugs; Tissue Distribution; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |
In vivo β-catenin attenuation by the integrin α5-targeting nano-delivery strategy suppresses triple negative breast cancer stemness and metastasis.
Topics: Animals; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Drug Delivery Systems; Humans; Integrin alpha5; Mice, Nude; Nanoconjugates; Neoplasm Invasiveness; Neoplastic Stem Cells; Oligopeptides; Triple Negative Breast Neoplasms; Wnt Signaling Pathway | 2019 |
Triple-hit therapeutic approach for triple negative breast cancers using docetaxel nanoparticles, EN1-iPeps and RGD peptides.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Docetaxel; Endocytosis; Female; Homeodomain Proteins; Humans; Mice; Mice, Inbred BALB C; Nanoparticles; NIH 3T3 Cells; Oligopeptides; Polymers; Tissue Distribution; Triple Negative Breast Neoplasms | 2019 |
Multitargeted Nanoparticles Deliver Synergistic Drugs across the Blood-Brain Barrier to Brain Metastases of Triple Negative Breast Cancer Cells and Tumor-Associated Macrophages.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Disease Progression; Doxorubicin; Drug Delivery Systems; Drug Synergism; Female; Humans; Lipids; Macrophages; Mice; Mitomycin; Nanoparticles; Oligopeptides; RAW 264.7 Cells; Receptors, LDL; Survival Analysis; Tissue Distribution; Triple Negative Breast Neoplasms | 2019 |
Correlative Light-Electron Microscopy Shows RGD-Targeted ZnO Nanoparticles Dissolve in the Intracellular Environment of Triple Negative Breast Cancer Cells and Cause Apoptosis with Intratumor Heterogeneity.
Topics: Apoptosis; Cell Death; Cell Line, Tumor; Genetic Heterogeneity; Humans; Light; MCF-7 Cells; Metal Nanoparticles; Microscopy, Electron; Oligopeptides; Triple Negative Breast Neoplasms; Zinc Oxide | 2016 |
Combinatorial nanocarrier based drug delivery approach for amalgamation of anti-tumor agents in breast cancer cells: an improved nanomedicine strategy.
Topics: Acrylic Resins; Antineoplastic Combined Chemotherapy Protocols; Chitosan; Drug Carriers; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; MCF-7 Cells; Nanoparticles; Oligopeptides; Quercetin; Silicon Dioxide; Topotecan; Triple Negative Breast Neoplasms | 2016 |
Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Screening Assays, Antitumor; Female; Humans; Lung Neoplasms; Mice; Mice, SCID; Mitomycin; Molecular Structure; Nanoparticles; Oligopeptides; Structure-Activity Relationship; Triple Negative Breast Neoplasms | 2017 |